Invex Therapeutics has outlined its commitment to corporate governance, including a code of conduct, whistleblower policy, and adherence to ethical standards, as part of its latest ESG report.
Material actions and disclosures
The company has a diversity policy in place, although it did not set measurable gender diversity objectives for the past financial year due to the existing skill and experience of its current directors and senior executives.
Invex Therapeutics also has a program for inducting new directors and ensuring existing directors undertake professional development to maintain the skills and knowledge needed to perform their roles effectively.
The company’s Corporate Governance Plan includes a Code of Conduct and a Whistleblower Protection Policy, both available on the Group’s website. The Board is informed of any material breaches of these policies.
Invex Therapeutics has also adopted an Environmental, Social and Governance (ESG) Policy and ESG Charter to manage and mitigate environmental and social risks.
Forward commitments
The company plans to continue its commitment to ethical standards and compliance with all applicable laws, rules, and regulations.
Invex Therapeutics will continue to evaluate and improve its risk management framework and internal control processes.
Attributed to the company’s latest ESG report.